Showing results (201-210 of 234) with videos related to
Sort By:
Pageof 24
American Journal of Hematology|August 18, 2017
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITYStuart L Goldberg, Jorge E Cortes, Carlo Gambacorti-Passerini, et al.Cancer|April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationFranck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2017
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE TrialJorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.Nature Genetics|September 19, 2018
Functional classification of long non-coding RNAs by k-mer contentJessime M Kirk, Susan O Kim, Kaoru Inoue, et al.Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid LeukemiaKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.Blood|October 22, 2009
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutationFranck E Nicolini, Michael J Mauro, Giovanni Martinelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.Leukemia|June 1, 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trialTim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, et al.Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.Pageof 24